Later studies demonstrated that EZH2 is upregulated in ovarian cancer and that this upregulation is associated with a high proliferation index, a high tumor grade, and poor prognosis (Di Croce and Helin, 2013). Here, EZH2 is linked to ovarian carcinoma.